Surgery for Gastrointestinal Metastases of Malignant Melanoma - a Single Center Retrospective Cohort Study

The aim is to conduct a single centre retrospective study of all patients with stage IV melanoma that underwent surgery for metastases at Sahlgrenska University Hospital between 2010-01-01 and 2018-12-31. Pre- and postoperative data will be collected from digital medical records, the Swedish Cancer Registry, the Swedish Cause of Death Register as well as from the national Swedish cancer patient database (INCA). If needed, patient records will be collected from other hospitals. Results will be presented in written format as a summary and analysis of the characteristics of the cases operated on during the inclusion period.

The aim is to identify predictive and prognostic factors for outcome and complications in the surgical treatment of stage IV metastatic melanoma.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Melanoma Stage IV Abdominal Neoplasms Abdominal Tumor Melanoma Melanoma Metastatic Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Germ Cell and Embryonal Neoplasms, Nerve Tissue Neuroectodermal Tumors Neuroendocrine Tumors Nevi and Melanomas Skin Diseases Skin Neoplasms Skin and Connective Tissue Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Sahlgrenska University Hospital

Gothenburg, 413 45, Sweden

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Biopsy verified stage IV malignant melanoma, stage M1c.
Having undergone surgery with metastasectomy of melanoma tumors.

Exclusion criteria

retroperitoneal tumors

Treatment and study plan

Abdominal surgery with metastasectomy

Procedure

Emergency or elective surgery on indications related to abdominally metastasized malignant melanoma

Primary outcomes

Overall survival

Time frame: December 2018

Overall survival

Secondary outcomes

Complications according to Clavien-Dindo within 90 days.

Time frame: 90 days

Complications according to Clavien-Dindo within 90 days.

Sponsors and collaborators

Lead sponsor

Vastra Gotaland Region

Other Gov

Registry information

Acronym: SurgMelMet

Important dates

Study start: 2010
Primary completion: 2018
Study completion: 2018
First posted: Mar 18, 2019
Registry last updated: Jan 26, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Active, Not Recruiting